NasdaqGS:ZBIOBiotechs
Zenas BioPharma (ZBIO) Valuation Check After New Convertible Notes And Equity Offerings
Zenas BioPharma (ZBIO) has drawn fresh attention after completing a US$200 million offering of 2.50% convertible senior notes due 2032, alongside a US$100 million follow-on equity sale at US$20 per share.
See our latest analysis for Zenas BioPharma.
The funding news comes after a sharp reset in sentiment, with a 30 day share price return of a 15% decline and a 90 day share price return of a 47.85% decline, while the 1 year total shareholder return stands at about 2.8x. Recent events include...